肝内胆管癌（ICC）是一种常见的侵袭性恶性肿瘤，5年生存率不到5%。目前，根治性手术切除是ICC的首选治疗方法。然而，大多数患者仅在晚期被诊断出来，因此无法接受手术治疗。在这篇文章中，我们介绍了一例晚期ICC，由于肿瘤侵犯到第二肝门和右肝动脉，无法进行根治手术。通过6个疗程的吉西他滨和奥沙利铂（GEMOX）化疗方案联合卡瑞利珠单抗免疫治疗，实现了部分缓解和成功的肿瘤转化，因为肿瘤对第二肝门和右肝动脉的侵犯不再明显。随后，患者成功接受了包括肝切除术、尾状叶切除术和胆囊切除术联合淋巴结清扫的根治手术。晚期ICC患者在联合免疫治疗和化疗后进行手术切除的病例很少见。GEMOX方案结合卡瑞利珠单抗展示了良好的抗肿瘤疗效和安全性，表明它可能是晚期ICC患者的潜在可行的转化治疗策略。版权所有 © 2023 Zhang, Wang, Li, Sun, Chen and Lin。

Intrahepatic cholangiocarcinoma (ICC) is one of the most common invasive malignant tumors, with a 5-year survival rate of less than 5%. Currently, radical surgical resection is the preferred treatment for ICC. However, most patients are only diagnosed at an advanced stage and are therefore not eligible for surgery. Herein, we present a case of advanced ICC in which radical surgery was not possible due to tumor invasion of the second porta hepatis and right hepatic artery. Six treatment cycles with a gemcitabine and oxaliplatin (GEMOX) regimen combined with camrelizumab immunotherapy achieved a partial response and successful tumor conversion, as tumor invasion of the second porta hepatis and right hepatic artery was no longer evident. The patient subsequently underwent successful radical surgical resection, including hepatectomy, caudate lobe resection, and cholecystectomy combined with lymph node dissection. Cases of patients with advanced ICC undergoing surgical resection after combined immunotherapy and chemotherapy are rare. The GEMOX regimen combined with camrelizumab demonstrated favorable antitumor efficacy and safety, suggesting that it might be a potential feasible and safe conversion therapy strategy for patients with advanced ICC.Copyright © 2023 Zhang, Wang, Li, Sun, Chen and Lin.